UI060

UI060 is a small molecule drug candidate being developed by Korea United Pharm as an Incrementally Modified Drug (IMD) within the non-steroidal anti-inflammatory drug (NSAID) class. Currently in the formulation stage, UI060 is designed to improve upon existing NSAID therapies, likely through an advanced delivery system such as a controlled-release formulation or a fixed-dose combination. The goal of such modifications in the NSAID category typically involves enhancing therapeutic efficacy, improving patient adherence, or mitigating common side effects like gastrointestinal irritation. As an NSAID, its primary mechanism of action involves the inhibition of cyclooxygenase enzymes, which are responsible for the biosynthesis of pro-inflammatory prostaglandins.